Abstract
Restless legs syndrome (RLS) is a sensorimotor disorder with the cardinal symptoms consisting of an urge to move the legs because of unpleasant sensations, appearing during rest or inactivity, worsening at evening or during the night, which are partially or totally recovered by movement [1]. Depending on the severity and frequency of the symptoms, RLS is often associated with insomnia and an impairment of quality of life [2]. Periodic leg movements (PLM) during sleep may be observed in more than 80% of RLS patients [3]. The pathogenesis of RLS is still unknown, but there are several pieces of evidence that advert to a possible dysfunction of descending dopaminergic neurons from the hypothalamic A11 region to the intermediolateral and dorsal spinal gray matter [4].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4(2):101–19.
Allen RP. Restless legs syndrome effects on quality of life. In: Ondo WG, editor. Restless legs syndrome diagnosis and treatment. New York: Informa Healthcare; 2007. p. 199–203.
Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12(1):61–5.
Rye DB. Parkinson’s disease and RLS: the dopaminergic bridge. Sleep Med. 2004;5(3):317–28.
Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006;28(8):1065–78.
Clemens S, Hochman S. Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knock-out mice. J Neurosci. 2004;24(50):11337–45.
Inami Y, Horiguchi J, Nishimatsu O, Sasaki A, Sukegawa T, Katagiri H, et al. A polysomnographic study on periodic limb movements in patients with restless legs syndrome and neuroleptic-induced akathisia. Hiroshima J Med Sci. 1997;46(4):133–41.
Chaudhuri KR. Iron and restless legs syndrome: the story unfolds. Sleep Med. 2006;7(5):395–6.
Michaud M, Dumont M, Selmaoui B, Paquet J, Fantini ML, Montplaisir J. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol. 2004;55(3):372–80.
Manconi M, Ferri R, Zucconi M, Oldani A, Fantini ML, Castronovo V, et al. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements. Sleep Med. 2007;8(5):491–7.
Montplaisir J, de Champlain J, Young SN, et al. Narcolepsy and idiopathic hypersomnia: biogenic amines and related compounds in CSF. Neurology. 1982;32:1299–302.
Aldrich MS, Hollingeswoth Z, Penney JB. Dopamine-receptor autoradiography of human narcoleptic brain. Neurology. 1992;42:410–5.
Kish SJ, Mamelak M, Slimovitch C, et al. Brain neurotransmitter changes in human narcolepsy. Neurology. 1992;42:229–34.
Rinne JO, Hublin C, Partinen M, et al. Positron emission tomography study of human narcolepsy: no increase in striatal dopamine D2 receptors. Neurology. 1995;45:1735–8.
Hublin C, Launes J, Nikkinen P, Partinen M. Dopamine D2-receptors in human narcolepsy: a SPECT study with 125I-IBZM. Acta Neurol Scand. 1995;90:186–9.
Rinne JO, Hublin C, Nagren K, Helenius H, Partinen M. Unchanged striatal dopamine transporter availability in narcolepsy: a PET study with [11C]-CFT. Acta Neurol Scand. 2004;109:52–5.
Honda K, Riehl J, Mignot E, Nishino S. Dopamine D3 agonists into the substratia nigra aggravates cataplexy but does not modify sleep. Neuroreport. 1999;10:3111–8.
Okura M, Riehl J, Mignot E, Nishino S. Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy. Neuropsychopharmacology. 2000;23:528–38.
Miller JD, Farber J, Gatz P, Roffwarg H, German DC. Activity of mesencephalic dopamine and non-dopamine neurons across stages of sleep and waking in the rat. Brain Res. 1983;273:133–41.
Piercey MF, Hoffmann WE, Smith MW, Hyslop DK. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol. 1996;312:35–44.
Nishino S, Honda K, Riehl J, Mignot E. Extracellular single unit recordings of dopaminergic neurons in the ventral tegmental area in narcoleptic dobermans. Sleep. 2000;23(S2):A1a.
Taheri S, Zeitzer JM, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci. 2002;25:283–313.
Hagan JJ, Leslie RA, Patel S, et al. Orexin A activates locus coeruleus cell firing and increases arousal in rat. Proc Natl Acad Sci USA. 1999;96:10911–6.
Nacamura T, Uramura K, Nambu T, et al. Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. Brain Res. 2000;873:181–7.
Wu MF, John J, Maidment N, Lam HA, Siegel JM. Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am J Physiol Regul Integr Comp Physiol. 2002;283:R1079–86.
Torterolo P, Yamuy J, Sampogna S, Morales FR, Chase MH. Hypocretinergic neurons are primarily involved in activation of the somatomotor system. Sleep. 2003;26:25–30.
Allen R, Mignot E, Ripley B, Hishino S, Early C. Increased CSF hypocretin (orexin) in idiopathic restless legs syndrome. Neurology. 2002;59:639–41.
Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001;18:128–47.
Stiasny-Kolster K, Mignot E, Ling L, Möller JC, Cassel W, Oertel WH. CSF hypocretin-1 levels in restless legs syndrome. Neurology. 2003;61(10):1426–9.
Mignot E, Lammers GJ, Ripley B, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002;59:1553–62.
Poceta JS, Parsons L, Engelland S, Kripke DF. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson’s disease. Sleep Med. 2009;10(1):129–33.
Bahammam A. Periodic leg movements in narcolepsy patients: impact on sleep architecture. Acta Neurol Scand. 2007;115:351–5.
Dauvilliers Y, Pennestri MH, Petit D, Dang-Vu T, Lavigne G, Montplaisir J. Periodic leg movements during sleep and wakefulness in narcolepsy. J Sleep Res. 2007;16:333–9.
Baker TL, Guilleminault C, Nino-Murcia G, Dement WC. Comparative polysomnographic study of narcolepsy and idiopathic central nervous system hypersomnia. Sleep. 1986;9:232–42.
Okura M, Fujiki N, Ripley B, et al. Narcoleptic canines display periodic leg movements during sleep. Psychiat Clin Neurosci. 2001;55:243–4.
Harsh J, Peszka J, Hartwig G, Mitler M. Night-time sleep and daytime sleepiness in narcolepsy. J Sleep Res. 2000;9:309–16.
Dauvilliers Y, Billiard M, Montplaisir J. Clinical aspects and pathophysiology of narcolepsy. Clin Neurophysiol. 2003;114:2000–17.
Scofield H, Roth T, Drake C. Periodic limb movements during sleep: population prevalence, clinical correlates, and racial differences. Sleep. 2008;31(9):1221–7.
Ferri R, Zucconi M, Manconi M, Bruni O, Ferini-Strambi L, et al. Different periodicity and time structure of leg movements during sleep in narcolepsy/cataplexy and restless legs syndrome. Sleep. 2006;29:1587–94.
Ferri R, Miano S, Bruni O, et al. NREM sleep alterations in narcolepsy/cataplexy. Clin Neurophysiol. 2005;116:2675–84.
Sforza E, Nicolas A, Lavigne G, Gosselin A, Petit D, et al. EEG and cardiac activation during periodic leg movements in sleep. Neurology. 1999;52:786–91.
Boivin DB, Montplaisir J, Poirier G. The effects of L-dopa on periodic leg movements and sleep organization in narcolepsy. Clin Neuropharmacol. 1989;12(4):339–45.
Boivin DB, Lorrain D, Montplaisir J. Effects of bromocriptine on periodic limb movements in human narcolepsy. Neurology. 1993;43:2134–6.
Bédard MA, Montplaisir J, Godbout R, Lapierre O. Nocturnal gamma-hydroxybutyrate. Effect on periodic leg movements and sleep organization of narcoleptic patients. Clin Neuropharmacol. 1989;12(1):29–36.
Abril B, Carlander B, Touchon J, Dauvilliers Y. Restless legs syndrome in narcolepsy: a side effect of sodium oxybate? Sleep Med. 2007;8:181–3.
Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol. 1997;51:337–61.
Roth T. Narcolepsy: treatment issues. J Clin Psychiatry. 2007;68 Suppl 13:16–9.
Rottach K, Schaner B, Kirch M, et al. Restless legs syndrome as a side effect of second generation antidepressants. J Psychiat Res. 2009;43:70–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Ferini-Strambi, L. (2011). The Motor System and Narcolepsy: Periodic Leg Movements and Restless Legs Syndrome. In: Baumann, C., Bassetti, C., Scammell, T. (eds) Narcolepsy. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-8390-9_28
Download citation
DOI: https://doi.org/10.1007/978-1-4419-8390-9_28
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-8389-3
Online ISBN: 978-1-4419-8390-9
eBook Packages: MedicineMedicine (R0)